B Streptococcus (GBS) Infection Treatment Market Analysis and Future Prospects for 2030
B Streptococcus (GBS) Infection Treatment Market Analysis and Future Prospects for 2030
Source: pr-inside.com
Stay updated with breaking news from Minervax Aps. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
B Streptococcus (GBS) Infection Treatment Market Analysis and Future Prospects for 2030
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has...
/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first...